✦ LIBER ✦

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome

✍ Scribed by Dale, D. C.; Bolyard, A. A.; Kelley, M. L.; Westrup, E. C.; Makaryan, V.; Aprikyan, A.; Wood, B.; Hsu, F. J.

Book ID: 121699470
Publisher: American Society of Hematology
Year: 2011
Tongue: English
Weight: 612 KB
Volume: 118
Category: Article
ISSN: 0006-4971
DOI: 10.1182/blood-2011-06-360586

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 1 clinical trial of long-term, l

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

✍ McDermott, D. H.; Liu, Q.; Velez, D.; Lopez, L.; Anaya-O'Brien, S.; Ulrick, J.; 📂 Article 📅 2014 🏛 American Society of Hematology 🌐 English ⚖ 529 KB

Relaxin is a renal vasodilator in experi

Relaxin is a renal vasodilator in experimental models of cirrhosis and a potential novel therapy for hepatorenal syndrome in man

✍ Snowdon, Victoria K; Pellicoro, Antonella; Ramachandran, Prakash; Mungall, Willi 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 51 KB

Semax, an analogue of adrenocorticotropi

Semax, an analogue of adrenocorticotropin (4–10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome

✍ Shih-Jen Tsai 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 83 KB